A pilot study of pembrolizumab and exemestane/leuprolide in premenopausal hormone receptor positive/HER2 negative locally advanced or metastatic breast cancer (PEER).

被引：0
|
作者：
Chen, I-Chun [1 ]
Lin, Ching-Hung [1 ]
Chang, Dwan-Ying [2 ]
Chen, Tom Wei-Wu [2 ]
Wang, Ming-Yang [1 ]
Ma, Wei-Li [2 ]
Lin, Yi-Ting [2 ]
Huang, Shu-Min [2 ]
Lu, Yen-Shen [2 ]
机构：
[1] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT028
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy
    Rozenblit, Mariya
    Pusztai, Lajos
    Adelson, Kerin
    Mougalian, Sarah
    CANCER RESEARCH, 2020, 80 (04)
  • [2] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [3] Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
    Fedele, Palma
    Orlando, Laura
    Schiavone, Paola
    Calvani, Nicola
    Caliolo, Chiara
    Quaranta, Annamaria
    Nacci, Angelo
    Cinieri, Saverio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (03) : 291 - 301
  • [4] Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape
    Redfern, Andrew
    Burslem, Katie
    Woodward, Natasha
    Beith, Jane
    Mccarthy, Nicole
    De Boer, Richard
    Bell, Richard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 19 - 31
  • [5] A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients
    Chan, Nancy
    Moore, Dirk
    Tandra, Pavankumar
    Rana, Jatin
    Omene, Coral
    George, Mridula
    Krishnamurthy, Jairam
    Desai, Shruti
    Patel, Nayana
    Wang, Yue
    Bicomong, Marc
    Tan, Xiao-Wei
    Hirshfield, Kim
    Ganesan, Shridar
    Toppmeyer, Deborah
    CANCER RESEARCH, 2022, 82 (04)
  • [6] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [7] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Irfan Cicin
    Hakan Karagol
    Ufuk Usta
    Atakan Sezer
    Sernaz Uzunoglu
    Rusen Alas-Cosar
    Tarkan Yetisyigit
    Kazim Uygun
    Medical Oncology, 2009, 26 : 335 - 343
  • [8] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Cicin, Irfan
    Karagol, Hakan
    Usta, Ufuk
    Sezer, Atakan
    Uzunoglu, Sernaz
    Alas-Cosar, Rusen
    Yetisyigit, Tarkan
    Uygun, Kazim
    MEDICAL ONCOLOGY, 2009, 26 (03) : 335 - 343
  • [9] ESTROGEN RECEPTOR AS A NEGATIVE PREDICTOR OF COMPLETE PATHOLOGICAL RESPONSE IN HER2 POSITIVE LOCALLY ADVANCED BREAST CANCER
    Canario, Rita
    Cruz, Jorge
    Casalta-Lopes, Joao
    Goncalves, Bruno
    Mariano, Monica
    Broco, Sofia
    Pais, Ana
    Pazos, Isabel
    Carvalho, Teresa
    Pego, Antonio
    Madeira, Pedro
    Sousa, Gabriela
    Gervasio, Helena
    BREAST, 2015, 24 : S46 - S46
  • [10] A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
    Schmid, Peter
    Sablin, Marie-Paule
    Bergh, Jonas
    Im, Seock-Ah
    Lu, Yen-Shen
    Martinez, Noelia
    Neven, Patrick
    Lee, Keun Seok
    Morales, Serafin
    Perez-Fidalgo, J. Alejandro
    Adamson, Douglas
    Goncalves, Anthony
    Prat, Aleix
    Jerusalem, Guy
    Schlieker, Laura
    Espadero, Rosa-Maria
    Bogenrieder, Thomas
    Huang, Dennis Chin-Lun
    Crown, John
    Cortes, Javier
    BREAST CANCER RESEARCH, 2021, 23 (01)
12345